MKI67 and non-small cell lung carcinoma: An increase in the frequency of PD-1+ CD8 T cells and an enhanced frequency of PD-1+ CD8 T cells that express Ki67 has previously been observed in NSCLC patients undergoing anti-PD-1/anti-PD-L1 therapy [20, 31].